{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:37Z","timestamp":1786951477509,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jdcr.2026.05.049","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T07:06:38Z","timestamp":1779865598000},"page":"14-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab"],"prefix":"10.1016","volume":"74","author":[{"given":"Andrew E.","family":"Craver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailish","family":"Hanly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9363-945X","authenticated-orcid":false,"given":"Matthew D.","family":"Vesely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2026.05.049_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-Associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.jdcr.2026.05.049_bib2","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jdcr.2026.05.049_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jdcr.2026.05.049_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2021.05.013","article-title":"Development of psoriasis during treatment with dupilumab: a systematic review","volume":"86","author":"Brumfiel","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.049_bib5","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.049_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamadermatol.2025.1578","article-title":"Psoriasis risk in patients with Atopic dermatitis treated with dupilumab","volume":"161","author":"Lin","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.049_bib7","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/ijd.17610","article-title":"Effectiveness and safety of combined dupilumab and risankizumab in concomitant atopic dermatitis and psoriasis","volume":"64","author":"Termini","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jdcr.2026.05.049_bib8","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.12788\/cutis.0858","article-title":"Concurrent atopic dermatitis and psoriasis successfully treated with dual biologic therapy","volume":"112","author":"Kaszycki","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.jdcr.2026.05.049_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris - part 2: specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdcr.2026.05.049_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2021.100021","article-title":"Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis","volume":"1","author":"Wang","year":"2021","journal-title":"JID Innov"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626003231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:38:03Z","timestamp":1786948683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626003231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"alternative-id":["S2352512626003231"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.049","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ostraceous psoriasis in end-stage renal disease: A delayed phenotype switch from dupilumab treated with guselkumab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}